Genomic instability at both the base pair level and the chromosomal level is detectable in earliest PanIN lesions in tissues of chronic pancreatitis

Pancreas

Volumn 39, Issue 7, 2010, Pages 1093-1103

  Baumgart, Mario ^a   Werther, Meike ^b   Bockholt, Anke ^c   Scheurer, Maria ^b   Rüschoff, Josef ^d   Dietmaier, Wolfgang ^e   Ghadimi, B Michael ^a   Heinmöller, Ernst ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b TARGOS Molecular Pathology GmbH   (Germany)

^c NORDSTADT HOSPITAL   (Germany)

^d Institute of Pathology Nordhessen   (Germany)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

aneuploidy; chronic pancreatitis; FISH; mutations; PanIN

Indexed keywords

K RAS PROTEIN; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CHROMOSOME; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME PAIRING; CHRONIC PANCREATITIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENOMIC INSTABILITY; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREATIC INTRAEPITHELIAL NEOPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; FEMALE; GENES, P16; GENES, RAS; GENOMIC INSTABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PRECANCEROUS CONDITIONS; SMAD4 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957325749     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181dc62f6     Document Type: Article

References (79)

1. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328:1433-1437.
2. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst. 1997;89:442-446.
3. Howes N, Greenhalf W, Neoptolemos J. Screening for early pancreatic ductal adenocarcinoma in hereditary pancreatitis. Med Clin North Am. 2000;84:719-738.
4. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2006;56:8-106.
6. Teich N, Mössner J. Molecular analysis of pancreatic juice: a helpful tool to differentiate benign and malignant pancreatic tumors? Dig Dis. 2004;22:235-238.
7. Grade M, Becker H, Ghadimi BM. The impact of molecular pathology in oncology: the clinician's perspective. Cell Oncol. 2004;26:275-278.
8. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:211-226.
9. Hruban RH, Adsay V, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia. A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579-586.
10. Moskaluk CA, Hruban RH, Kern SE. P16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997;57:2140-2143.
11. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002-2006.
12. Heinmöller E, Dietmaier W, Zirngibl H, et al. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol. 2000;157:83-92.
13. Yamano M, Fujii H, Takagaki T, et al. Genetic progression and divergence in pancreatic carcinoma. Am J Pathol. 2000;156:2123-2133.
14. Lüttges J, Galehdari H, Bröcker V, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol. 2001;158:1677-1683.
15. van Heek TN, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol. 2002;161:1541-1547.
16. Buchholz M, Braun M, Heidenblut A, et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene. 2005;24:6626-6636.
17. Abraham SC, Wilentz RE, Yeo CJ, et al. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all "chronic pancreatitis"? Am J Surg Pathol. 2003; 27:110-120.
18. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol. 2003;16:996-1006.
19. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1731-1734.
20. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57:3126-3130.
21. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909.
22. Gansauge S, Schmid RM, Muller J, et al. Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations. Br J Surg. 1998;85:337-340.
23. Gerdes B, Ramaswamy A, Kersting M, et al. P16INK4a alterations in chronic pancreatitis - indicator for high-risk lesions for pancreatic cancer. Surgery. 2001;129:490-497.
24. Fukushima N, Sato N, Ueki T, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol. 2002;160:1573-1581.
25. Heinmöller E, Bockholt A, Werther M, et al. Laser microdissection of small tissue samples - application to chronic pancreatitis tissues. Pathol Res Pract. 2003;199:363-371.
26. Rivera JA, Rall CJN, Graeme-Cook F, et al. Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. Surgery. 1997;121:42-49.
27. Yanagisawa A, Ohtrake K, Ohashi K, et al. Frequent Kras oncogene activation in mucous cell hyperplasia of pancreas suffering from chronic inflammation. Cancer Res. 1993;53:953-956.
28. Lüttges J, Diederichs A, Menke MAOH, et al. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer. 2000;88:2495-2504.
29. Löhr M, Klöppel G, Maisonneuve P, et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia. 2005;7:17-23.
30. Stanger BZ, Stiles B, Lauwers GY, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell. 2005;8:185-195.
31. Stanger BZ, Dor Y. Dissecting the cellular origins of pancreatic cancer. Cell Cycle. 2006;5:43-46.
32. Maitra A, Hruban RH. A new mouse model of pancreatic cancer: PTEN gets its Akt together. Cancer Cell. 2005;8:171-172.
33. Hruban RH, Pitman MB, Klimstra DS. AFIP Atlas of Tumor Pathology, Series IV. Tumors of the Pancreas. Washington, DC: American Registry of Pathology; 2007.
34. Ottenhof NA, Milne AN, Morsink FH, et al. Pancreatic intraepithelial neoplasia and pancreatic tumorigenesis: of mice and men. Arch Pathol Lab Med. 2009;133(3):375-381.
35. Amman RW, Heitz PU, Klöppel G. Course of alcoholic chronic pancreatitis: a prospective clinicomorphological long-term study. Gastroenterology. 1996;111:224-231.
36. Detlefsen S, Sipos B, Feyerabend B, et al. Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Arch. 2005;447:800-805
37. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977-987.
38. Heinmöller E, Qiang L, Sun Y, et al. Toward efficient analysis of mutations in single cells from ethanol-fixed, paraffin-embedded, and immunohistochemically-stained tissues. Lab Invest. 2002;82:443-453.
39. Dietmaier W, Hartmann A, Wallinger S, et al. Multiple mutation analyses in single tumor cells enabled by improved whole genome amplification. Am J Pathol. 1999;154:83-95.
40. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995;11:210-212.
41. Hahn SA, Shamsul Hoque ATM, Moskaluk CA, et al. Homozygous deletions map at 18q21.1 in pancreatic cancer. Cancer Res. 1996;56:490-494.
42. Schlegel J, Bocker T, Zirngibl H, et al. Detection of microsatellite instability in human colorectal carcinomas using a non-radioactive PCR-based screening method. Virchows Arch. 1995;426:223-227.
43. Shuber AP, Grondin VJ, Klinger KW. A simplified procedure for developing multiplex PCRs. Genome Res. 1995;5:488-493.
44. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000.
45. Baas IO, Mulder JWR, Offerhaus GJA, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994;172:5-12.
46. Hedley DW. DNA analysis from paraffin-embedded blocks. Methods Cell Biol. 1994;41:231-240.
47. Mehta CR, Pantel NR. A network algorithm for performing Fisher's exact test in r x c contingency tables. J Am Stat Assoc. 1983;78:427-434.
48. Gorunova L, Johansson B, Dawiskiba S, et al. Massive cytogenetic heterogeneity in a pancreatic carcinoma: fifty-four karyotypically unrelated clones. Genes Chromosomes Cancer. 1995;14:259-266.
49. Gorunova L, Höglund M, Andren-Sandberg A, et al. Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer. 1998;23:81-99.
50. Solinas-Toldo S, Wallrapp C, Muller-Pillasch F, et al. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res. 1996;56(16):3803-3807.
51. Ghadimi BM, Schröck E, Walker RL, et al. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator in pancreatic carcinomas. Am J Pathol. 1999;154:525536.
52. Mahlamäki EH, Bärlund M, Tanner M, et al. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer. 2002;35(4):353-358.
53. Harada T, Okita K, Shiraishi K, et al. Interglandular cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer. Cancer Res. 2002;62(3):835-839.
54. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17:3112-3126.
55. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469-483.
56. De La O JP, Emerson LL, Goodman JL, et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A. 2008;105(48):18907-18912.
57. Shi C, Hong SM, Lim P, et al. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res. 2009;7:230-236.
58. Tang ZH, Zou SQ, Hao YH, et al. The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma. Hepatobiliary Pancreat Dis Int. 2002;1:624-629.
59. McCarthy DM, Brat DJ, Wilentz RE, et al. Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. Hum Pathol. 2001;32:638-642.
60. Rosty C, Geradts J, Sato N, et al. P16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol. 2003;27:1495-1501.
61. Zhang L, Sanderson SO, Lloyd RV, et al. Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2007;31:1191-1195.
62. Takaori K, Matsusue S, Fujikawa T, et al. Carcinoma in situ of the pancreas associated with localized fibrosis: a clue to early detection of neoplastic lesions arising from pancreatic ducts. Pancreas. 1998;17:102-105.
63. Takaori K, Kobashi Y, Matsusue S, et al. Clinicopathological features of pancreatic intraepithelial neoplasias and their relationship to intraductal papillary-mucinous tumors. J Hepatobiliary Pancreat Surg. 2003;10:125-136.
64. Brat DJ, Lillemoe KD, Yeo CJ, et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol. 1998;22:163-169.
65. Brockie E, Anand A, Albores-Saavedra J. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma. Ann Diagn Pathol. 1998;2:286-292.
66. Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res. 1998;58:4740-4744.
67. Duesberg P, Fabarius A, Hehlmann R. Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells. IUBMB Life. 2004;56:65-81.
68. Feldser DM, Hackett JA, Greider CW. Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer. 2003;3:623-627.
69. Bielas JH, Loeb LA. Mutator phenotype in cancer: timing and perspectives. Environ Mol Mutagen. 2005;45(2-3):206-213.
70. Michor F, Iwasa Y, Vogelstein B, et al. Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol. 2005;15:43-49.
71. Li L, McCormack AA, Nicholson JM, et al. Cancer-causing karyotypes: chromosomal equilibria between destabilizing aneuploidy and stabilizing selection for oncogenic function. Cancer Genet Cytogenet. 2009;188:1-25.
72. Moskovitz AH, Linford NJ, Brentnall TA, et al. Chromosomal instability in pancreatic ductal cells from patients with chronic pancreatitis and pancreatic adenocarcinoma. Genes Chromosomes Cancer. 2003;37:201-206.
73. Soldini D, Gugger M, Burckhardt E, et al. Progressive genomic alterations in intraductal papillary mucinous tumours of the pancreas and morphologically similar lesions of the pancreatic ducts. J Pathol. 2003;199:453-461.
74. Kozuka S, Sassa R, Taki T, et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer. 1979;43:1418-1428.
75. Furukawa T, Chiba R, Kobari M, et al. Varying grades of epithelial atypia in the pancreatic ducts of humans. Classification based on morphometry and multivariate analysis and correlated with positive reactions of carcinoembryonic antigen. Arch Pathol Lab Med. 1994;118(3):227-234.
76. Suda K, Nobukawa B, Yamasaki S, et al. Invasive ductal adenocarcinoma of the pancreas may originate from the larger pancreatic duct: a study of 13 tumors less than 2 cm in diameter. J Hepatobiliary Pancreat Surg. 2007;14:283-288.
77. DiGiuseppe JA, Hruban RH, Offerhaus GJ, et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol. 1994;144:889-895.
78. Li R, Sonik A, Stindl R, et al. Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. Proc Natl Acad Sci U S A. 2000;97:3236-3241.
79. Michor F, Iwasa Y, Nowak MA. Dynamics of cancer progression. Nat Rev Cancer. 2004;4:197-205.